Related Experiment Videos
[Captopril and hypertensive cardiopathy : therapeutic effects and hormonal changes]
V Palazzuoli1, S Mondillo, M Galli
1Istituto di Clinica Medica Generale e Terapia Medica, Università degli Studi, Siena.
Insights
Captopril effectively lowers blood pressure in hypertensive patients with heart failure. This ACE inhibitor significantly impacts hormonal levels, including aldosterone, plasma renin activity, and atrial natriuretic factor, in patients with advanced heart failure.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Context:
- Hypertension is a leading cause of heart failure.
- Understanding the hemodynamic and hormonal effects of antihypertensive drugs is crucial.
- Previous studies have not fully elucidated the complex hormonal responses to ACE inhibitors in heart failure patients.
Purpose:
- To investigate the acute effects of captopril on hemodynamic and hormonal parameters in hypertensive patients with and without heart failure.
- To explore the underlying mechanisms of altered hormonal responses in heart failure patients treated with captopril.
Summary:
- A single oral dose of captopril (50 mg) was administered to 12 hypertensive patients (6 normal hemodynamics, 6 NYHA class III/IV heart failure).
- Mean arterial pressure decreased similarly in both groups, but hormonal variations (aldosterone, plasma renin activity, atrial natriuretic factor) were greater in the heart failure group.
- The study proposes impaired hepatic angiotensinogen production in heart failure leads to reduced aldosterone, increased renin, and decreased atrial natriuretic factor.
Impact:
- Provides insights into the differential hormonal responses to ACE inhibitors in heart failure.
- Suggests potential mechanisms for improved myocardial contractility and reduced intra-atrial pressure in heart failure patients.
- Highlights the complex interplay between the renin-angiotensin system, atrial natriuretic factor, and cardiac function in hypertension-induced heart failure.
Abstract:
The effect of a single oral dose (50 mg) of captopril was studied in 12 hypertensive patients divided into 2 groups: 6 had a normal hemodynamic profile; the other 6 had NYHA class III or IV heart failure. Medical history and clinical and laboratory investigation showed that the heart failure was due exclusively to arterial hypertension. Mean arterial pressure (MAP), aldosterone, plasma renin activity (PRA) and atrial natriuretic factor (ANF) were followed for 4 hours after administration of captopril. MAP values showed a similar decrease in the 2 groups but the variations in the 3 hormones were much greater in the second group. This group showed higher basal levels of PRA, aldosterone and ANF; after stimulation PRA increased sharply preceded by a substantial decrease in aldosterone and ANF. To explain this phenomenon, the Authors propose that the liver of the patients with heart failure is unable to rapidly compensate the reduction in synthesis of angiotensin II caused by the drug with a corresponding increase in angiotensinogen production; the consequent sharp drop in plasma aldosterone would lead to a rise in renin production by the kidney. The arteriolar and venous vasodilatation induced by the ACE-inhibitor, would explain the drop in intra-atrial pressure with reduced plasma levels of ANF. The decrease in ANF could also be caused by the inhibition of the renin-angiotensin system of the heart leading to improved blood supply and hence myocardial contractility.